Llwytho...
Monitoring Molecular Response in Chronic Myeloid Leukemia
BACKGROUND: Prior to the advent of tyrosine kinase inhibitor (TKI) therapy, the evaluation of hematologic and cytogenetic responses was sufficient to gauge treatment efficacy in patients with chronic myeloid leukemia. However, with more potent TKI therapies, the majority of patients achieve complete...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cancer |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2010
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4969001/ https://ncbi.nlm.nih.gov/pubmed/20960522 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25527 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|